Advertisement
ALGN vs IDXX
Which Stock Would AI Choose? Align Technology (ALGN) vs. IDEXX Laboratories (IDXX) Stock Comparison
Key Takeaways
- Both ALGN and IDXX have posted positive year-to-date (YTD) gains around 14-16%, reflecting resilience in the healthcare sector amid market volatility.
- ALGN recently beat Q1 earnings expectations with revenue of $1.04 billion and EPS (earnings per share) of $2.58, followed by a $200 million stock repurchase announcement, boosting recent momentum.
- IDXX approaches its Q1 earnings release with strong expectations for 11.9% revenue growth, driven by its Companion Animal Group, though some analyst targets have been adjusted lower recently.
- IDXX trades at a premium valuation with a trailing PE (price-to-earnings) ratio of 43.3 versus ALGN's 30.0, highlighting differing growth perceptions.
- Over the past month, ALGN has outperformed with approximately 5% gains, while IDXX has been relatively flat.
- Both stocks exhibit high betas above 1.5, indicating elevated volatility compared to the broader market.
Introduction
Align Technology (ALGN) and IDEXX Laboratories (IDXX) represent distinct niches within the healthcare sector: ALGN dominates clear aligner therapy through its Invisalign system, while IDXX leads in animal health diagnostics and software solutions. This stock comparison is relevant for growth-oriented investors and traders seeking exposure to specialized medtech plays with recurring revenue streams. In the current market environment, characterized by sector rotation and anticipation of earnings, understanding their relative performance, valuations, and catalysts aids in evaluating positioning for potential trades or portfolio adjustments.
ALGN Overview and Recent Performance
Align Technology (ALGN) is the global leader in invisible orthodontics, primarily through its Invisalign clear aligners and iTero intraoral scanners, serving a vast network of orthodontists and general dentists. The company's business model emphasizes digital workflows and direct-to-consumer expansion in emerging markets. In recent market activity, ALGN shares have climbed, trading around $179 with a market capitalization of approximately $12.8 billion. Key drivers include a strong Q1 beat on revenue and EPS, record clear aligner volumes, and a $200 million open-market repurchase program, which have lifted sentiment and prompted analyst price target increases to an average of $209. YTD performance stands at about 14.6%, with recent weeks showing upward momentum amid margin improvements, though the stock remains below its 52-week high of $208.
IDXX Overview and Recent Performance
IDEXX Laboratories (IDXX) specializes in veterinary diagnostics, practice management software, and consumables for companion animals, water testing, and livestock, with the Companion Animal Group as its primary growth engine. The firm benefits from steady demand in pet healthcare and recurring revenue from reference labs and instruments. Recently, IDXX shares hover near $567, supported by a $45 billion market cap. Performance has been solid YTD at 16.1%, though flatter over the past month amid pre-earnings positioning for Q1 results expected to show robust growth in diagnostics. Sentiment reflects consistent historical EPS beats, tempered by select analyst caution, with an average price target of $725 despite some reductions. The stock trades well off its 52-week peak of $770.
Trending AI Robots
Tickeron’s Trending AI Robots page curates 25 top-performing AI trading bots from its library of 351, spotlighting those best suited to prevailing market conditions across stocks, ETFs, and crypto. These bots showcase impressive stats, including annualized returns up to 163%, win rates of 59-75%, profit factors exceeding 3 in leading examples, and profit-to-drawdown ratios around 5-6, with average trade durations from 2-8 days. Diverse strategies—spanning technical patterns, fundamentals, and sector themes like semiconductors or small caps—enable varied risk profiles and timeframes. While none currently feature ALGN or IDXX prominently, the platform's full suite covers thousands of tickers. Traders may explore these bots for automated signals and copy-trading opportunities tailored to dynamic environments.
Head-to-Head Comparison
ALGN and IDXX both leverage proprietary tech in niche healthcare verticals, but diverge in scale and end-markets: ALGN's consumer-facing aligners contrast IDXX's B2B veterinary ecosystem. Growth drivers include ALGN's international expansion and digital tools versus IDXX's recurring diagnostics revenue. Recent momentum favors ALGN post-earnings, while IDXX eyes its report for confirmation. Valuation trade-offs are stark—ALGN's forward PE of 15.9 signals relative value against IDXX's 39.4—though IDXX offers greater stability with higher margins. Risks encompass economic sensitivity to elective procedures for ALGN and pet spending cycles for IDXX; both face high betas (1.7 and 1.6) amplifying market swings. Sentiment tilts positive for both, buoyed by healthcare tailwinds.
Tickeron AI Verdict
Tickeron’s AI models currently lean toward ALGN with higher probability in the near term, citing fresher catalysts like the earnings beat and buyback for sustained trend consistency, alongside a more attractive forward valuation and recent outperformance. IDXX remains compelling for stability and growth reliability, particularly post-earnings, but its premium pricing tempers relative appeal amid broader market positioning.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALGN is a Hold and IDXX is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALGN’s FA Score shows that 0 FA rating(s) are green whileIDXX’s FA Score has 1 green FA rating(s).
- ALGN’s FA Score: 0 green, 5 red.
- IDXX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALGN’s TA Score shows that 4 TA indicator(s) are bullish while IDXX’s TA Score has 4 bullish TA indicator(s).
- ALGN’s TA Score: 4 bullish, 6 bearish.
- IDXX’s TA Score: 4 bullish, 4 bearish.
Price Growth
ALGN (@Pharmaceuticals: Other) experienced а -4.12% price change this week, while IDXX (@Medical Specialties) price change was -0.24% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.97%. For the same industry, the average monthly price growth was -0.88%, and the average quarterly price growth was -13.78%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.28%. For the same industry, the average monthly price growth was +13.41%, and the average quarterly price growth was -7.34%.
Reported Earning Dates
ALGN is expected to report earnings on Jul 29, 2026.
IDXX is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-2.97% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (-3.28% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| ALGN | IDXX | ALGN / IDXX | |
| Capitalization | 12B | 44.3B | 27% |
| EBITDA | 877M | 1.56B | 56% |
| Gain YTD | 7.422 | -16.905 | -44% |
| P/E Ratio | 28.19 | 41.37 | 68% |
| Revenue | 4.1B | 4.45B | 92% |
| Total Cash | 1.06B | 201M | 527% |
| Total Debt | 116M | 1.11B | 10% |
ALGN | IDXX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 64 | 11 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 70 Overvalued | 82 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 92 | |
SMR RATING 1..100 | 69 | 16 | |
PRICE GROWTH RATING 1..100 | 57 | 60 | |
P/E GROWTH RATING 1..100 | 66 | 66 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ALGN's Valuation (70) in the Medical Specialties industry is in the same range as IDXX (82). This means that ALGN’s stock grew similarly to IDXX’s over the last 12 months.
IDXX's Profit vs Risk Rating (92) in the Medical Specialties industry is in the same range as ALGN (100). This means that IDXX’s stock grew similarly to ALGN’s over the last 12 months.
IDXX's SMR Rating (16) in the Medical Specialties industry is somewhat better than the same rating for ALGN (69). This means that IDXX’s stock grew somewhat faster than ALGN’s over the last 12 months.
ALGN's Price Growth Rating (57) in the Medical Specialties industry is in the same range as IDXX (60). This means that ALGN’s stock grew similarly to IDXX’s over the last 12 months.
ALGN's P/E Growth Rating (66) in the Medical Specialties industry is in the same range as IDXX (66). This means that ALGN’s stock grew similarly to IDXX’s over the last 12 months.
| ALGN | IDXX | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 72% | N/A |
| Stochastic ODDS (%) | 3 days ago 74% | 3 days ago 63% |
| Momentum ODDS (%) | 3 days ago 75% | 3 days ago 57% |
| MACD ODDS (%) | 3 days ago 71% | 3 days ago 65% |
| TrendWeek ODDS (%) | 3 days ago 72% | 3 days ago 71% |
| TrendMonth ODDS (%) | 3 days ago 77% | 3 days ago 72% |
| Advances ODDS (%) | 10 days ago 71% | 4 days ago 60% |
| Declines ODDS (%) | 5 days ago 74% | 12 days ago 69% |
| BollingerBands ODDS (%) | 3 days ago 62% | 3 days ago 61% |
| Aroon ODDS (%) | 3 days ago 77% | 3 days ago 80% |
Advertisement